BiotechTube

Buparlisib & Paclitaxel

Phase 3Completed
0 views this week 0 watching💤 Quiet
Interest: 30/100
30
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Head and Neck Cancer

Conditions

Head and Neck Cancer

Trial Timeline

Dec 12, 2020 → Nov 2, 2025

NCT ID
NCT04338399

About Buparlisib & Paclitaxel

Buparlisib & Paclitaxel is a phase 3 stage product being developed by Adlai Nortye for Head and Neck Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT04338399. Target conditions include Head and Neck Cancer.

What happened to similar drugs?

11 of 20 similar drugs in Head and Neck Cancer were approved

Approved (11) Terminated (0) Active (9)
✅Galcanezumab-GnlmEli LillyApproved
✅Ubrogepant 50 MG [Ubrelvy] + Ubrogepant 100 MG [Ubrelvy]AbbVieApproved
✅Placebo + Zolmitriptan + Zolmitriptan + ZolmitriptanAstraZenecaApproved
✅Propranolol or nadolol + Placebo control + Optimal Acute TherapyMerckApproved
✅Pembrolizumab + Carboplatin + PaclitaxelMerckApproved
✅Erenumab 70 mg + Erenumab 140 mg + PlaceboAmgenApproved
✅Rimegepant + ZavegepantPfizerApproved

Hype Score Breakdown

Clinical
17
Activity
8
Company
5
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT04338399Phase 3Completed

Competing Products

20 competing products in Head and Neck Cancer

See all competitors
ProductCompanyStageHype Score
Abametapir Lotion 0.74% w/w + Vehicle LotionDr. Reddy's LaboratoriesPhase 3
37
DFN-15 ActiveDr. Reddy's LaboratoriesPhase 3
37
Ha44 Gel 0.74% w/wDr. Reddy's LaboratoriesPhase 2
32
Abametapir Lotion 0.74% w/w + Vehicle LotionDr. Reddy's LaboratoriesPhase 3
37
Abametapir Lotion 0.74% w/wDr. Reddy's LaboratoriesPhase 1
26
DFN-11 InjectionDr. Reddy's LaboratoriesPhase 2
24
Abametapir Lotion 0.74% w/w + Sodium Lauryl Sulfate + Saline 0.9% + PlaceboDr. Reddy's LaboratoriesPhase 1
26
Abametapir Lotion 0.74% w/w + Vehicle LotionDr. Reddy's LaboratoriesPhase 2
32
Ha44 GelDr. Reddy's LaboratoriesPhase 2
32
AFM24 + SNK01AffimedPhase 1/2
14
Cemiplimab + CetuximabEli LillyPhase 2
42
BB-401Benitec BiopharmaPhase 2
25
Placebo + LY2300559Eli LillyPhase 2
27
Gemcitabine + ACR-368Acrivon TherapeuticsPhase 2
32
Ketorolac + Prochlorperazine + DiphenhydramineAssertio HoldingsPhase 2
17
Ramucirumab + PembrolizumabEli LillyPhase 2
39
Ozuriftamab Vedotin + Pembrolizumab + Evalstotug (BA3071) + CetuximabBioAtlaPhase 2
25
Patritumab + Cetuximab + Cisplatin + Carboplatin + PlaceboDaiichi SankyoPhase 2
27
Patritumab + Cetuximab + Cisplatin + CarboplatinDaiichi SankyoPhase 1
29
cevimeline hydrochlorideDaiichi SankyoPhase 3
40